Maravai LifeSciences Holdings, Inc. (MRVI)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
7.06 USD
-0.38
(-5.108%) ⇩
(Oct. 12, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:39 a.m. EDT
The investment case here is fundamentally broken. The company has endured four consecutive years of negative annual returns, culminating in a catastrophic -91.79% cumulative decline over the last four years. This is not a temporary setback; the market has repeatedly punished the stock, and the price action confirms a structural deterioration where the business is failing to generate value. Despite a recent headline about a patent win and a narrowing loss, the financial reality remains dire: negative operating cash flow, negative free cash flow, and a return on equity of -33%. The balance sheet is fragile with debt significantly exceeding cash reserves. There is no dividend to provide income, and the stock trades at a premium to book value despite earning nothing. The options market reflects this despair, with traders buying deep puts to protect against further ruin rather than calling for a recovery. With no evidence of a turnaround in the multi-year trajectory and a balance sheet under strain, this is a clear avoid. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.096248 |
| AutoETS | 0.096276 |
| MSTL | 0.096531 |
| AutoARIMA | 0.182319 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.713 |
| Excess Kurtosis | -0.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 61.335 |
| Revenue per Share | 1.429 |
| Market Cap | 2,614,725,376 |
| Forward P/E | -70.14 |
| Beta | 0.54 |
| Profit Margins | -37.07% |
| Website | https://www.maravai.com |
As of Oct. 10, 2026, 9:39 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes $5.00 and $7.50) compared to negligible call volume. While there is some speculative call activity at distant strikes ($10.00-$12.50), the capital allocation heavily favors hedging against further declines rather than betting on a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1857586 |
| Address1 | 10,770 Wateridge Circle |
| Address2 | Suite 200 |
| All Time High | 63.55 |
| All Time Low | 1.665 |
| Ask | 8.96 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.9 - Buy |
| Average Daily Volume10 Day | 2,928,170 |
| Average Daily Volume3 Month | 3,297,835 |
| Average Volume | 3,297,835 |
| Average Volume10Days | 2,928,170 |
| Beta | 0.544 |
| Bid | 5.25 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.374 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.06 |
| Current Ratio | 4.052 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 7.381 |
| Day Low | 6.95 |
| Debt To Equity | 61.335 |
| Display Name | Maravai LifeSciences |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,050,000 |
| Earnings Call Timestamp Start | 1,786,050,000 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -19,745,000 |
| Ebitda Margins | -0.09458 |
| Enterprise To Ebitda | -68.414 |
| Enterprise To Revenue | 6.47 |
| Enterprise Value | 1,350,840,192 |
| Eps Current Year | -0.10739 |
| Eps Forward | -0.10066 |
| Eps Trailing Twelve Months | -0.53 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.1797 |
| Fifty Day Average Change | -0.119699955 |
| Fifty Day Average Change Percent | -0.016672 |
| Fifty Two Week Change Percent | 118.57586 |
| Fifty Two Week High | 9.42 |
| Fifty Two Week High Change | -2.3600001 |
| Fifty Two Week High Change Percent | -0.2505308 |
| Fifty Two Week Low | 2.545 |
| Fifty Two Week Low Change | 4.515 |
| Fifty Two Week Low Change Percent | 1.7740667 |
| Fifty Two Week Range | 2.545 - 9.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,605,882,600,000 |
| Float Shares | 106,403,863 |
| Forward Eps | -0.10066 |
| Forward P E | -70.13709 |
| Free Cashflow | -3,623,125 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 415 |
| Fullday Change | -0.4920001 |
| Fullday Change Percent | -6.612905 |
| Fullday Price | 7.06 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.35707 |
| Gross Profits | 74,548,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.072270006 |
| Held Percent Institutions | 0.99082 |
| Implied Shares Outstanding | 370,357,705 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-11-20 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California. |
| Long Name | Maravai LifeSciences Holdings, Inc. |
| Market | us_market |
| Market Cap | 2,614,725,376 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_573282023 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -77,386,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,098,052,946 |
| Number Of Analyst Opinions | 6 |
| Open | 7.38 |
| Operating Cashflow | -25,261,000 |
| Operating Margins | -0.29396 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 858 546 0004 |
| Previous Close | 7.44 |
| Price Eps Current Year | -65.741684 |
| Price Hint | 2 |
| Price To Book | 5.1382823 |
| Price To Sales Trailing12 Months | 12.52413 |
| Profit Margins | -0.37067002 |
| Quick Ratio | 2.635 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.88889 |
| Region | US |
| Regular Market Change | -0.38 |
| Regular Market Change Percent | -5.10753 |
| Regular Market Day High | 7.381 |
| Regular Market Day Low | 6.95 |
| Regular Market Day Range | 6.95 - 7.381 |
| Regular Market Open | 7.38 |
| Regular Market Previous Close | 7.44 |
| Regular Market Price | 7.06 |
| Regular Market Time | 1,791,835,201 |
| Regular Market Volume | 1,252,195 |
| Return On Assets | -0.05708 |
| Return On Equity | -0.33046 |
| Revenue Growth | 0.085 |
| Revenue Per Share | 1.429 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 148,989,545 |
| Shares Percent Shares Out | 0.0928 |
| Shares Short | 13,826,066 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,963,180 |
| Short Name | Maravai LifeSciences Holdings, |
| Short Percent Of Float | 0.1099 |
| Short Ratio | 5.22 |
| Source Interval | 15 |
| State | CA |
| Symbol | MRVI |
| Target High Price | 9.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 7.83333 |
| Target Median Price | 8.0 |
| Total Cash | 70,091,000 |
| Total Cash Per Share | 0.47 |
| Total Debt | 218,099,008 |
| Total Revenue | 208,775,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.53 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.972025 |
| Two Hundred Day Average Change | 2.087975 |
| Two Hundred Day Average Change Percent | 0.4199446 |
| Type Disp | Equity |
| Volume | 1,252,195 |
| Website | https://www.maravai.com |
| Zip | 92,121 |